Science Innovation Forum

Science & Innovation Forum – The Impact of Red Blood Cell Transfusions on Biomarkers of Hemorrhagic Shock and Traumatic Brain Injury

Please note: AABB reserves the right to make updates to this program.
Presented by Hemanext^®, an AABB Premium Corporate Partner.

Optimizing healthcare for patients sustaining a traumatic brain injury is of major concern given the high incidence of death and disabilities. Traumatic brain injury (TBI) may be accompanied by hemorrhage and coagulopathy. Treatment of combined hemorrhagic shock (HS) and TBI is particularly challenging because the two therapeutic treatment strategies for TBI and HS often conflict. This program will provide an overview of the biomarkers of HS and TBI and the impact of red blood cell transfusions on these events.

After attending this program, participants should be able to:

• Discuss the prognostic significance of lactate in trauma.
• Describe the significance of biomarkers in traumatic brain injury.
• Identify the innovations in hemorrhagic shock resuscitation and traumatic brain injury.
• Describe the impact of red blood cells on traumatic brain injury and hemorrhagic shock biomarkers.

Intended Audience

CEOs, CFOs, COOs, Directors, Donor Recruitment Staff, Facilities that perform molecular testing, Hospital Blood Banks, Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Research Scientists, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers.

Registration

This Science & Innovation Forum is complimentary to all, but registration is required. By registering for this AABB-hosted program you consent to have your information shared with the program sponsor, Hemanext^®.